stockportfolio.pro
BioMarin Pharmaceutical Inc. (BMRN)
Healthcare · Biotechnology · NasdaqGS
BioMarin Pharmaceutical Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $1.31B | $1.49B | $1.70B | $1.86B | $1.85B | $2.10B | $2.42B | $2.85B | $3.22B |
| Gross profit | $907.23M | $1.07B | $1.18B | $1.34B | $1.34B | $1.38B | $1.59B | $1.89B | $2.27B | $2.50B |
| Net income | $-630.21M | $-117.04M | $-77.21M | $-23.85M | $854.03M | $-64.08M | $141.56M | $167.65M | $426.86M | $348.90M |
| Net margin | -56.4% | -8.9% | -5.2% | -1.4% | 45.9% | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
Source: BioMarin Pharmaceutical Inc. SEC filings (10-K). 18 years of history available in the interactive view.
Explore 18 years of BioMarin Pharmaceutical Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BMRN in your portfolio →
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
BioMarin Pharmaceutical Inc. — frequently asked questions
What is BioMarin Pharmaceutical Inc.'s revenue?
BioMarin Pharmaceutical Inc. (BMRN) reported revenue of $3.22B for fiscal year 2025, up 12.9% from the prior year, according to its SEC filings.
Is BioMarin Pharmaceutical Inc. profitable?
Yes. BMRN earned net income of $348.90M in fiscal 2025, a net margin of 10.8%.
What is BMRN's P/E ratio?
BioMarin Pharmaceutical Inc. trades at a price-to-earnings ratio of about 40.4 based on the latest data in our nightly-refreshed cache.
How fast is BioMarin Pharmaceutical Inc. growing?
BMRN's revenue grew at roughly 11.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from BioMarin Pharmaceutical Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.